HCRN BRE18-334
A Phase II circulating tumor DNA enriched, genomically directed post-neoadjuvant trial for patients with residual triple negative breast cancer (PERSEVERE)
Status: Open to Accrual
Linked In
You Tube
Breast
HCRN BRE18-360
Phase I/II Study of Stereotactic Radiosurgery with Concurrent Administration of Olaparib Followed by Adjuvant Combination of Durvalumab and Physician’s Choice Systemic Therapy in Subjects with Breast Cancer Brain Metastases
Status: Open to Accrual
HCRN BRE19-433
A Multi-institutional Phase II Study to Evaluate Efficacy and Safety of TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 negative Patients with PD-L1+ Metastatic Triple Negative Breast Cancer (TARA)
Status: Open to Accrual
HCRN BRE21-516
BRIDGET: Secondary BRain metastases prevention after Isolated intracranial progression on Trastuzumab/Pertuzumab or T-DM1 in patients with aDvanced human epidermal Growth factor receptor 2+ brEast cancer with the addition of Tucatinib
Status: Open to Accrual
TBCRC044
A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease
Status: Open to Accrual
TBCRC046
A Phase II Trial of Avelumab or Hydroxychloroquine with or without Palbociclib to Eliminate Dormant Breast Cancer (“PALAVY”)
Status: Open to Accrual
TBCRC047
Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A Multicenter, Multi-Arm Translational Breast Cancer Research Consortium Study
Status: Open to Accrual
BTCRC-BRE15-024
A phase I/II, single arm, non-randomized study of ribociclib (LEE011), a CDK 4/6 inhibitor in combination with bicalutamide, an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer: Big Ten Cancer Research Consortium BTCRC-BRE15-024
Status: Open to Accrual
BTCRC-BRE16-042
A Phase II Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients: Big Ten Cancer Research Consortium BTCRC-BRE16-042
Status: Open to Accrual
BTCRC-BRE18-337
Phase 2 Trial With Safety Run-In of Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers: Big Ten Cancer Research Consortium BTCRC-BRE18-337
Status: Open to Accrual
BTCRC-BRE19-409
A Phase II, Single Arm, Non-randomized Study of Alpelisib (BYL719) in Combination with Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer: Big Ten Cancer Research Consortium BTCRC-BRE19-409
Status: Open to Accrual
HCRN BRE12-158
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients with Triple Negative Breast Cancer.
Status: Closed to Accrual
TBCRC029
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Closed to Accrual
TBCRC035
Palbociclib in Combination with Fulvestrant or Tamoxifen as Treatment for Hormone Receptor Positive Metastatic Breast Cancer with Prior Chemotherapy for Advanced Disease: A Phase II study with Pharmacodynamics Markers (TBCRC035)
Status: Closed to Accrual
BTCRC-BRE15-016
A Single Arm Phase II Study of Palbociclib in Combination with Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer: Big Ten Cancer Research Consortium BTCRC-BRE15-016
Status: Closed to Accrual
Facebook
Hoosier Cancer Research Network on Facebook
Linked In
You Tube
Twitter